OptionsHouse

Options Trading News

October 12, 2012  Fri 7:31 AM CT

LXRX: SEE CHART GET CHAIN FIND STRATEGIES

Drug Progresses to Final Stage of Testing

Lexicon Pharmaceuticals reported positive data for its drug that treats carcinoid tumors. It's now moving from Phase 2 trials to Phase 3 trials, sending LXRX higher by 13 percent in the premarket.

Infosys Sees Weaker Profit

Infosys now expect full-year earnings of $2.97 a share, versus its previous forecast of $3.03.The outsourcing company also failed to raise it revenue guidance as analysts had hoped. INFY drops 5 percent in early trading.

J.B. Hunt Revenue Beats Expectations

J.B. Hunt Transport Services had third-quarter revenue of $1.30 billion, beating the $1.28 billion estimate. Profit missed expectations, but investors are focusing on that strong top-line number and sending JBHT higher by about 5 percent in the premarket.

Weak PC Market Drags on AMD

Advanced Micro Devices preannounced that third-quarter revenue fell by about 10 percent. It had previously forecast a decline of no more than 4 percent. Management cited a weakening PC market, and AMD is lower by 9 percent in the pre.

Share this article with your friends


OptionsHouse

TRADING WEEKLY OPTIONS

The fastest money in the market
View full report »

Premium Services

Archived Webinar

Education & Strategy

Real vs. Synthetic

We now know that there are two ways of creating a call position, a put position, and a stock position. We can simply use the actual real security or we can recreate it synthetically. We can create these positions in both long and short forms and this ability sets up an interesting scenario--an arbitrage!

View more education articles »